{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:48:54Z","timestamp":1789858134851,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jbspin.2019.07.011","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T11:50:42Z","timestamp":1564401042000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte"],"prefix":"10.1016","volume":"87","author":[{"given":"C\u00e9cile","family":"Dumaine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bekkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Belot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"von Scheven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"Carbasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Woerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenza","family":"Bouayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Hentgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2019.07.011_bib0160","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0165","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jbspin.2017.08.001","article-title":"New classification for juvenile idiopathic arthritis: Is the Tower of Babel falling?","volume":"85","author":"Belot","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1546-0096-12-13","article-title":"Treatment of juvenile idiopathic arthritis: a revolution in care","volume":"12","author":"Stoll","year":"2014","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0175","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/rheumatology\/kes114","article-title":"Assessing the safety of biologic agents in patients with rheumatoid arthritis","volume":"51","author":"Rubbert-Roth","year":"2012","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0180","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jbspin.2010.12.004","article-title":"Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review","volume":"78","author":"Baronnet","year":"2011","journal-title":"Bone Spine Rev Rhum"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11926-016-0572-1","article-title":"Fungal Infections and New Biologic Therapies","volume":"18","author":"Vallabhaneni","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0195","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/BTT.S2210","article-title":"Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences","volume":"2","author":"Stoll","year":"2008","journal-title":"Biol Targets Ther"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0205","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0210","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","volume":"73","author":"Horneff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0215","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0220","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0225","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0230","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0235","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/rheumatology\/keu457","article-title":"Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting","volume":"54","author":"Tarkiainen","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0240","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13023-015-0228-7","article-title":"Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey","volume":"10","author":"Rossi-Semerano","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0245","first-page":"SR35","article-title":"Etanercept treatment in juvenile idiopathic arthritis: the Polish registry","volume":"17","author":"Zuber","year":"2011","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0250","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0255","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/acr.22961","article-title":"Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry","volume":"69","author":"Becker","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0260","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","article-title":"High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis","volume":"70","author":"Au","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0265","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2169\/internalmedicine.54.3103","article-title":"Fatal complication of Legionella pneumophila pneumonia in a tocilizumab-treated rheumatoid arthritis patient","volume":"54","author":"Arinuma","year":"2015","journal-title":"Intern Med Tokyo Jpn"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0270","first-page":"53","article-title":"Necrotizing Soft Tissue Infection Caused by Serratia marcescens in a Patient Treated with Tocilizumab","volume":"89","author":"Matsuo","year":"2015","journal-title":"Kansensh\u014dgaku Zasshi J Jpn Assoc Infect Dis"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0275","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11926-013-0327-1","article-title":"Infectious complications in juvenile idiopathic arthritis","volume":"15","author":"Hurd","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0280","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00296-014-3197-6","article-title":"Incidence of herpes zoster infections in juvenile idiopathic arthritis patients","volume":"35","author":"Nimmrich","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0285","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/14740338.2015.1042453","article-title":"Safety of biologic therapies for the treatment of juvenile idiopathic arthritis","volume":"14","author":"Horneff","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0290","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1517\/14740338.2015.993605","article-title":"Safety issues and concerns of new immunomodulators in rheumatology","volume":"14","author":"Selmi","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0295","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/art.37866","article-title":"Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis","volume":"65","author":"Beukelman","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0300","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0305","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12969-019-0305-x","article-title":"The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis","volume":"17","author":"Nagy","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jbspin.2019.07.011_bib0310","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11926-015-0542-z","article-title":"Biologic-associated infections in pediatric rheumatology","volume":"17","author":"Horneff","year":"2015","journal-title":"Curr Rheumatol Rep"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X19301174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X19301174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:25:42Z","timestamp":1761150342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X19301174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1297319X19301174"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2019.07.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736323477.793582476","asserted-by":"object"}]},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2019.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}